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Abstract
The mechanism underlying the chronicity of hepatitis B virus (HBV) infection has long been an interesting question.
However, this mechanism remains unclear largely due to the lack of an animal model that can support persistent HBV
replication and allow for the investigation of the relevant immune responses. In this study, we used hydrodynamic injection
to introduce HBV replicon DNA into the livers of three different mouse strains: BALB/c, C57BL/6, and FVB/N. Interestingly, we
found that an HBV clone persistently replicated in the livers of FVB/N mice for up to 50 weeks but was rapidly cleared from
the livers of BALB/c and C57BL/6 mice. Flow cytometric analysis and quantitative reverse transcription PCR analysis of the
mouse livers indicated that after DNA injection, FVB/N mice had few intrahepatic activated cytotoxic T lymphocytes (CTLs)
and produced low levels of alanine aminotransferase, interferon (IFN)-c, tumor necrosis factor (TNF)-a, and the CXCL9 and
CXCL10 chemokines. These findings were in sharp contrast with those observed in BALB/c and C57BL/6 mice, reflecting a
strong correlation between the degree of liver inflammation and viral clearance. Mutational analysis further demonstrated
that a change of Asn-214 to Ser-214 in the HBV surface antigen rendered the persistent HBV clone clearable in FVB/N mice,
which was accompanied by increased levels of activated CTL and upregulated expression of IFN-c, CXCL9, and CXCL10 in
the livers. These results indicate that the heterogeneity of the host factors and viral sequences may influence the immune
responses against HBV. An inadequate activation of immune or inflammatory responses can lead to persistent HBV
replication in vivo.
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Introduction
With an estimated 350 million people worldwide chronically
infected, hepatitis B virus (HBV) infection remains a major health
problem. More than 95% of acutely infected adults recover from
the infection, whereas most of the neonatally transmitted infections
become persistent [1,2]. Chronic HBV infection can lead to
hepatic cirrhosis and hepatocellular carcinoma (HCC) [3].
Although a prophylactic vaccine against HBV is currently
available, HBV carriers who already have viral DNA in their
livers still run a great risk of developing HCC. An investigation of
the mechanisms underlying HBV persistence in vivo may lead to
new approaches for treating and preventing the progression of
chronic hepatitis B to life-threatening liver diseases.
The genetic background of the host and viral factors are
believed to contribute to the different outcomes of HBV infection.
Genetic polymorphisms of several host factors have been
implicated in the susceptibility to chronic HBV infection,
including estrogen receptor [4], killer cell immunoglobulin-like
receptor (KIR) [5], interleukin 10 promoter [6], interferon-c (IFN-
c) [7], tumor necrosis factor-alpha (TNF-a) promoter [8–10], and
human leukocyte antigen (HLA) class II molecules [11,12]. Among
these factors, IFN-c and TNF-a are two cytokines that can inhibit
HBV replication non-cytopathically [13–16]. The genetic varia-
tions leading to low levels of IFN-c and TNF-a production are
associated with chronic HBV infection [7–10]. In addition, a
recent genome-wide study has shown the HLA-DP loci belonging
to HLA class II molecules to also be associated with chronic HBV
infection, most likely due to a weaker CD4 T-cell helper response
induced by these HLA molecules [17].
In addition to host factors, several viral factors have been
reported to affect the innate or adaptive immune responses
against HBV infection. The hepatitis e antigen (HBeAg) is a
viral immunomodulatory protein that, via deletion or anergy,
inhibits the HBV core (HBcAg)/HBeAg cross-reactive T-cell
response [18]. The soluble hepatitis B surface antigen (HBsAg)
significantly exhausts HBsAg-specific T-cell responses [19].
HBV polymerase blocks pattern-recognition receptor signaling
by disrupting the interaction between IKKe and DDX3, a
DEAD box RNA helicase [20]. Furthermore, it is likely that
sequence diversity between different HBV genotypes or
different HBV strains may influence the existence of particular
epitopes, thus resulting in different immune response profiles
[21–23].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36984An easily generated immunocompetent animal model is
instrumental to the systematic investigation of host and/or viral
factors pertinent to HBV persistence. Although mice cannot be
infected by wild-type HBV, mouse hepatocytes can support HBV
replication and produce infectious virions when viral DNA is
directly delivered into the cells. Therefore, a genetically well-
characterized inbred mouse should be an ideal model to study the
mechanism of HBV persistence if HBV DNA can be efficiently
and appropriately delivered to the mouse liver. We have
previously employed hydrodynamic injection to deliver HBV
replicon DNA, cloned in a pGEM4Z plasmid vector, into BALB/
c, C57BL/6, and FVB/N mice. Surprisingly and interestingly,
persistent HBV replication was maintained in FVB/N mice for up
to 50 weeks but was rapidly diminished in BALB/c and C57BL/6
mice. Thus, we used these mouse strains to further investigate the
host and viral factors pertaining to HBV persistence. In this study,
we provide data demonstrating that mouse strains that elicit strong
cytotoxic T lymphocyte (CTL) responses and induce strong
inflammatory responses, e.g., BALB/c and C57BL/6, can clear
HBV rapidly, whereas mice that induce low levels of CTL and
weak inflammatory responses, e.g., FVB/N mice, tend to develop
a persistent infection. In addition, we show that a single amino
acid difference in the HBV surface protein can affect the activation
of CTL responses and result in different rates of viral persistence.
Results
Host genetic backgrounds influence HBV persistence in vivo
We first examined how host backgrounds might affect HBV
persistence in vivo. BALB/c (H-2
d), C57BL/6 (H-2
b), and FVB/N
(H-2
q) mice were hydrodynamically injected with a pHBV1.3-B6
replicon DNA that contains a 1.3-fold overlength of a genotype B
HBV genome (Fig. S1). To mimic the quasispecies status of HBV
in clinical settings, the B6 replicon DNA actually consists of six
sub-clones derived from the same chronic hepatitis B patient (see
the Materials and Methods). After DNA injection, serum HBeAg
was used as a surrogate marker to monitor HBV persistence in vivo.
The results revealed HBeAg to be rapidly cleared from the sera of
BALB/c (Fig. 1A) and C57BL/6 mice (Fig. 1B) within four and
eight weeks, respectively. In contrast, serum HBeAg persisted in
most of the FVB/N mice for up to 50 weeks (Fig. 1C) and had
cleared in only 1 out of 9 mice at 14 weeks post injection (wpi).
The HBeAg-positive rates in FVB/N mice were statistically
significant compared to those in BALB/c and C57BL/6 mice
(Fig. 1D).
To ascertain the persistence of HBV in FVB/N mice, Southern
blot analysis and immunohistochemical (IHC) staining were
performed on the livers. HBV replicative intermediates and the
episomal form of the injected DNA were detected in the livers of
BALB/c mice injected with the pHBV1.3-B6 replicon DNA for up
to two weeks (Fig. 2A) and in the livers of C57BL/6 mice for up to
five weeks (Fig. 2B) versus up to 29 weeks in the livers of FVB/N
mice (Fig. 2C). IHC staining of the liver sections also showed that
HBcAg and HBsAg were persistently expressed in FVB/N mice
but were rapidly cleared in BALB/c and C57BL/6 mice (Fig. 2D).
Cytoplasmic HBcAg has been reported to be an indicator of HBV
replication [24–26], whereas nuclear HBcAg is a stable species in
the absence of HBV replication [27,28]. Thus, the cytoplasmic
staining pattern of HBcAg in the livers of FVB/N mice (Fig. 2D)
Figure 1. Long-term follow up of serum HBeAg in the animals injected with the pHBV1.3-B6 replicon DNA. Serum HBeAg was monitored
regularly following hydrodynamic injection of pHBV1.3-B6 replicon DNA (10 mg/mouse) in BALB/c (A), C57BL/6 (B), and FVB/N (C) mice. Each line
represents one animal. The levels of HBeAg in 10-fold diluted sera are shown as S/CO, signal-to-control ratio. The dotted gray lines represent the cut-
off value of HBeAg. (D) The kinetics of HBeAg clearance in the three mouse strains over a period of 50 weeks are shown and were compared using the
logrank test. The HBeAg-positive rates are as follows: BALB/c,C57BL/6 (**P,0.01), BALB/c,FVB/N (***P,0.001), and C57BL/6,FVB/N (***P,0.001).
doi:10.1371/journal.pone.0036984.g001
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these mice at week 29. Collectively, these results demonstrate that
the pHBV1.3-B6 replicon DNA replicates persistently in FVB/N
mice but not in BALB/c and C57BL/6 mice.
HBeAg clearance correlates with elevated levels of
alanine aminotransferase (ALT), increased activated CTLs,
and the severity of inflammation in the livers
To pursue the mechanisms underlying the different clearance
rates of HBeAg in BALB/c, C57BL/6, and FVB/N mice, we
examined the severity of liver damage, the presence of activated
CTLs, and the status of liver inflammation. Serum ALT levels in
the DNA-injected animals were measured in order to determine
the severity of liver damage. As shown in Fig. 3A, a huge and
transient ALT peak (1500–2000 U/L) was immediately observed
one day after DNA injection in all three mouse strains tested, most
likely due to the acute liver damage induced by hydrodynamic
injection. A second, moderate ALT peak was observed in the
BALB/c mice at 2 wpi (,200 U/L), and in the C57BL/6 mice at
6 wpi (,150 U/L). In both mouse strains, the ALT levels
eventually normalized. However, the ALT levels in the FVB/N
mice, once recovering from the acute liver damage, remained
slightly elevated relative to the normal range (between 40–100 U/
L), a state that was maintained for at least 29 weeks (data not
shown). The results indicate that injection of HBV DNA in FVB/
N mice induces less liver damage than in BALB/c and C57BL/6
mice.
Effector CD8
+ CTLs are thought to play an important role in
the clearance of HBV infection; they are also implicated in the
pathogenesis of liver diseases [29,30]. Therefore, we examined the
levels of activated CTLs in the BALB/c, C57BL/6, and FVB/N
mouse strains after HBV DNA injection. Intrahepatic lymphocytes
(IHLs) were isolated and analyzed by flow cytometry. As shown in
Fig. 3B and Fig. S2, the levels of CD3
+CD8
+CD69
+ activated
CTLs were elevated as early as 2 wpi in the BALB/c mice
(,40%), and they peaked at 3 wpi in the C57BL/6 mice (,25%).
IFN-c enzyme-linked immunospot (ELISPOT) assays demonstrat-
ed that the CTLs isolated from the peak levels displayed significant
reactivities to the HBs, HBc, or polymerase peptides (Fig. S3 and
Methods S1), suggesting that they were HBV-specific. On the
other hand, the levels of activated CTLs in the FVB/N mice were
not significantly elevated (,5%) throughout the entire course of
the experiment. Thus, the levels of activated CTL strongly
correlated with the severity of liver damage in BALB/c, C57BL/6,
and FVB/N mice.
Next, we examined the inflammatory status of the livers in the
DNA-injected animals. The liver expression of inflammatory or
pro-inflammatory cytokines, such as IFN-c and TNF-a, was
examined by quantitative reverse transcription PCR (qRT-PCR).
In both the BALB/c and C57BL/6 mouse strains, IFN-c (Fig. 3C)
and TNF-a (Fig. 3D) were significantly induced slightly prior to or
simultaneously with ALT elevation, whereas the expression of
IFN-c and TNF-a remained low in the FVB/N mice. The small
peaks of IFN-c or TNF-a expression in the FVB/N mice during
Figure 2. The duration of HBV replicative intermediates present in the livers of the replicon DNA-injected animals. BALB/c (A), C57BL/
6 (B), and FVB/N (C) mice were hydrodynamically injected with 10 mg of the pHBV1.3-B6 replicon DNA. At the indicated time points, two animals were
sacrificed. The liver genomic DNA was extracted and digested with HindIII (a single cut in the HBV replicon DNA), and then analyzed using Southern
blot analysis with an HBV-specific probe. Each lane represents one animal. The sizes corresponding to the injected DNA, and the replicative
intermediates are indicated on the right. (D) The IHC staining of HBcAg and HBsAg in the livers of the BALB/c, C57BL/6, and FVB/N mice injected with
pHBV1.3-B6 DNA. Livers were harvested at the time points indicated. IHC staining was performed using anti-HBc or anti-HBs antibody on frozen
sections. The scale bar represents 100 mm. The images are displayed at 2006magnification.
doi:10.1371/journal.pone.0036984.g002
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minimal liver damage caused by hydrodynamic injection, as
injection with pGEM4Z vector also demonstrates similar peaks.
Previous studies by Guidotti et al. have shown that the IFN-c
expressed by activated CTLs not only clears HBV non-
cytopathically but also induces the expression of chemokines such
as CXCL9 and CXCL10, which in turn recruit antigen non-
specific mononuclear cells, resulting in liver pathogenesis and viral
clearance [29,30]. Because we observed different levels of IFN-c
and TNF-a in the different mouse strains studied, we compared
the expression levels of CXCL9 and CXCL10 in the livers of these
mouse strains. As expected, both CXCL9 and CXCL10 were
expressed at the highest levels in the BALB/c mice, at the second
highest levels in the C57BL/6 mice, and at the lowest levels in the
FVB/N mice (Figs. 3E and 3F). The hematoxylin and eosin (H&E)
staining results revealed the inflammatory status of the livers, as
shown in Fig. 4. The livers of the BALB/c mice exhibited severe
inflammation at 2 wpi, which was reduced at 3 wpi and
normalized at 5 wpi. Liver inflammation in the C57BL/6 mice
was much more moderate relative to that of the BALB/c mice.
Figure 3. The kinetics of ALT elevation, infiltration of activated CTLs, and the expression of cytokines and chemokines in different
mousestrainsafterDNA injection. Mice wereinjectedwith pHBV1.3-B6 DNA(10 mg/mouse),andthreeanimals weresacrificedatthe indicatedtime
pointsafterDNAinjection. (A)Theserum ALT levelsof the mice weremeasured.Thegraydashedlinesrepresentthe normalserum ALT levels, 40 U/L.(B)
Flow cytometric analysis of the levels of activated CTLs in the livers. Intrahepatic lymphocytes were isolated and stained for CD3 (PerCP), CD8 (FITC), and
CD69 (PE). The percentages of CD69-positive cells in the CD3- and CD8-double positive lymphocytes were determined by flow cytometry. In addition,
the liver expression of (C) IFN-c, (D) TNF-a, (E) CXCL9, and (F) CXCL10 was analyzed by qRT-PCR. Values are shown as the mean 6 SD.
doi:10.1371/journal.pone.0036984.g003
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cantly increased at 3–5 wpi, and returned to normal at 7 wpi. Not
surprisingly, the livers of the FVB/N mice displayed only slight
infiltration of inflammatory cells from 2 wpi to 29 wpi.
Collectively, these data indicate that the injection of HBV DNA
into the liver induces different degrees of T-cell activation and liver
inflammation in different mouse strains, and the mice can be
ordered by the degree of inflammation as follows: BALB/c mice
.C57BL/6 mice .FVB/N mice. The degree of liver inflamma-
tion strongly correlated with the animal’s ability to clear the HBV
DNA.
HBV viral sequences affect HBV persistence in FVB/N
mice
The low levels of IFN-c and inflammatory cells in the FVB/N
mice may suggest that this mouse model has little or no ability to
induce CTL activity in response to HBV replication. However,
although clone B6 and another HBV isolate (B22) persistently
replicated in the FVB/N mouse livers, other HBV isolates from
different patients (e.g., B21 and B29) were cleared within 10–20
weeks (Fig. 5A). The lower persistence rates of clones B21 and
B29, however, were not due to the lower replication or gene
expression efficiency of these clones relative to that of the B6 and
B22 clones (Fig. S4). These data suggested that FVB/N mice were
capable of mounting an immune response to clear HBV, although
this response remained weaker than that of BALB/c mice. With
Figure 4. Histological analysis of the livers from different mouse
strains injected with HBV DNA. BALB/c, C57BL/6, and FVB/N mice
were injected with the pHBV1.3-B6 replicon DNA. The mice were
sacrificed at the time points indicated, and their livers were fixed with
formalin, embedded in paraffin, and stained with hematoxylin and eosin.
The arrows indicate the infiltrating inflammatory cells. The scale bar
represents 100 mm. The images are displayed at 2006magnification.
doi:10.1371/journal.pone.0036984.g004
Figure 5. Different persistence rates of different HBV isolates. (A) The replicon DNA used for injection included pHBV1.3-B6, -B21, -B22, and -
B29 isolated from different patients. The kinetics of HBeAg clearance over a period of 20 weeks are shown. (B) The replicon DNA of the six sub-clones
(B6.1, B6.2, B6.3, B6.7, B6.8, and B6.9) contained in the B6 clone was injected separately into the FVB/N mice. Serum HBeAg was monitored for 20
weeks. The dotted gray lines represent the cut-off value of HBeAg. (C) The HBeAg-positive rate of each sub-clone is shown at 20 weeks post injection.
doi:10.1371/journal.pone.0036984.g005
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36984regard to the B6 clone, we speculate that this clone may possess
inherent characteristics that allow it to escape the CTL response in
FVB/N mice.
We next investigated the impact of viral factors on HBV
persistence. The persistence rates were analyzed among the six
sub-clones (B6.1, B6.2, B6.3, B6.7, B6.8, and B6.9) contained in
the B6 clone. These sub-clones had ,0.5% nucleotide sequence
diversity compared to the B6 consensus sequences (data not
shown). Interestingly, when injected separately into the FVB/N
mice, clone B6.9 demonstrated a lower persistent rate than did the
others (Figs. 5B and 5C). Sequence analysis revealed that clone
B6.9 had mutations at amino acid 337 of the polymerase (H337Y)
and at amino acid 214 of the surface protein (N214S), both
mutations that were not present in other sub-clones (Table 1).
Therefore, we investigated whether the variation of these two
amino acid residues conferred the susceptibility of clone B6.9 to
immune responses. The sequence of clone B6.2, one of the highly
persistent sub-clones (Fig. 5B), is the closest to the sequence of
clone B6.9. As a result, we performed site-directed mutagenesis on
clone B6.2 for persistence analysis. Clone B6.2S contains an
N214S mutation in the surface protein region, clone B6.2P
contains an H337Y mutation in the polymerase region, and clone
B6.2SP has both mutations. When injected separately into the
FVB/N mice, clones B6.2S (Fig. 6A) and B6.2SP (Fig. 6C) showed
significantly higher clearance rates than did the parental clone
(B6.2), whereas clone B6.2P (Fig. 6B) showed no significant
difference in clearance compared with the parental strain (Fig. 6D).
These results clearly indicate that the Ser-214 residue in the
surface protein represents a critical residue responsible for the
clearance of clone B6.9 in the FVB/N mice and indicate that a
one-residue difference (B6.2S vs. B6.2) can lead to significantly
different persistence rates.
Next, we examined whether the clearance of clone B6.2S was
also associated with the induction of inflammation. Although
serum ALT levels were not significantly elevated in the FVB/N
Table 1. Mutation sites of the amino acid residues in the six
sub-clones compared to the B6 consensus sequence.
Amino acid changes in ORF
Sub-clone X C S P
B6.1 identical identical L200H identical
B6.2 G44D, N149T identical identical V302M, V805M
B6.3 identical identical E39A R219S
B6.7 identical identical P69L D126E, V302M, C602G
B6.8 A12T identical I68T, T125A H305R, F307V, C602G
B6.9 G44D identical N214S H337Y, V805M
doi:10.1371/journal.pone.0036984.t001
Figure 6. Different persistence rates conferred by a single amino acid change in the HBV surface protein. The mutant replicon DNAs,
including (A) pHBV1.3-B6.2S, containing an N214S point mutation in surface protein; (B) pHBV1.3-B6.2P, containing an H337Y point mutation in
polymerase; and (C) pHBV1.3-B6.2SP, containing both N214S and H337Y mutations, were injected into FVB/N mice. The levels of HBeAg in 10-fold
diluted sera are shown as S/CO, signal-to-control ratio. Each line represents one animal. The dotted gray lines represent the cut-off value of HBeAg.
(D) The kinetics of HBeAg clearance in the mice injected with the wild-type sub-clone B6.2 or the three mutants (B6.2S, B6.2P, and B6.2SP) are shown
and were compared using the logrank test. The HBeAg-positive rates are B6.2S,B6.2 (**P,0.01), B6.2SP,B6.2 (*P,0.05), and B6.2P vs. B6.2, no
significance.
doi:10.1371/journal.pone.0036984.g006
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activated CTLs were increased in the mice injected with B6.2S
(,6%) compared with those injected with B6.2 (Fig. 7B). This
CTL increase was accompanied with slight, but significant,
elevations in the levels of intrahepatic IFN-c, TNF-a, CXCL9,
and CXCL10 (Figs. 7C–7F). The H&E staining results showed
that the livers of the FVB/N mice injected with clone B6.2
exhibited little to no infiltration of inflammatory cells, whereas the
FVB/N mice injected with clone B6.2S demonstrated more
infiltration of inflammatory cells, especially at 7 wpi (Fig. 8).
The epitope sequence motifs restricted to H-2
q have not been
reported. Thus, it is not clear whether the single N214S mutation
may generate a potential CTL epitope leading to the clearance of
clone B6.2S in the FVB/N mice. To test this possibility, we
performed ELISPOT assays using the IHLs isolated from the
animals injected with B6.2S. The IHLs were pulsed with two 15-
mer peptides that had the wild-type or the N214S mutated residue
located in the center of the 10-amino acid overlapped region (Fig.
S5A). It is anticipated that these two peptides, once processed, be
able to generate octapeptide epitopes that have the mutated
residue possibly located at position 1 to 8. However, the results of
the ELISPOT assays did not detect any peptide-specific CTL
response either with the wild-type or with the N214S peptide (Fig.
S5B). We speculated that the CTL frequency in the FVB/N mice
might be too low to be detected as the CTL activation and
inflammatory responses in the FVB/N mice injected with the
B6.2S DNA were much lower than those observed in the BALB/c
mice injected with pHBV1.3-B6 DNA (Fig. 3 vs. Fig. 7). Therefore,
we used an alternative approach to determine whether this
mutated sequence could serve as a potential epitope to induce
CTLs. FVB/N mice were intramuscularly immunized with a
plasmid DNA expressing either the wild-type or the mutated
HBsAg containing the N214S residue and were subsequently
boosted every two weeks for three times (Methods S1). An
ELISPOT assay using the aforementioned peptides was performed
on the splenocytes one week after the final boost. However, even
with such vigorous immunization procedures, the peptide-specific
T-cell responses were still not detected in the FVB/N mice (Fig.
S5C), whereas HBsAg-specific T-cell responses were easily
detected in the C57BL/6 mice with just two immunizations (Fig.
S5D). These results may suggest that the N214S mutated sequence
is not the T-cell epitope. However, this possibility has not been
formerly excluded.
Collectively, these results reinforced the association of HBV
clearance with the activation of CTLs, IFN-c expression, and the
subsequent induction of inflammation. Moreover, they indicate
that a difference in a single or a few amino acids in HBV can lead
to different immune responses and differences in the ultimate fate
of the virus.
Discussion
In this study, we have employed hydrodynamic injection to
introduce HBV replicon DNA into mouse livers. Whereas the
replicon DNA was rapidly cleared from the livers of the BALB/c
and C57BL/6 mice in four and eight weeks, respectively, it
persistently replicated and induced low levels of ALT elevation in
the livers of the FVB/N mice for up to 50 weeks. It is noteworthy
that FVB/N mice possess competent immune responses as
evidenced by the complete clearance of some HBV clones
(Fig. 5A). However, an estimated 50% of the HBV clones from
clinical isolates were able to replicate persistently in the FVB/N
mice (data not shown), indicating that persistent replication is not
an isolated event for the HBV1.3-B6 clone. Although 100% of the
isolates were cleared in BALB/c and C57BL/6 mice, the factors
that allow persistent HBV replication in FVB/N mice are peculiar
and interesting and were explored in this study.
In humans, there is a clear difference in the adaptive immunity
between patients with persistent, chronic HBV infections and
patients who resolve the infection. The development of strong
HBV-specific cellular immunity with Th1-type cytokine production
is usually associated with the resolution of the HBV infection,
whereas a weaker or undetectable cellular immune response that is
unable to control HBV replication is present in patients with
chronic HBV infection [13,31]. Moreover, through the use of
transgenic mice and adoptive transfer techniques, Guidotti and
Chisari have demonstrated that both CTLs and antigen-nonspecific
inflammatory cells are important for viral clearance [29,30]. In line
withthese reports, ourresults demonstratedthat the HBV clearance
strongly correlates with the presence of intrahepatic CTLs and the
severity of the liver inflammation during viral infection. Using
genetic approaches, we further demonstrated that viral sequences
also played influential roles in determining the HBV persistence. A
single amino acid change of Asn-214 to Ser-214 in the HBsAg
rendered an otherwise persistent HBV clone clearable in FVB/N
mice. Collectively, the HBV persistence in the nontransgenic FVB/
N mouse model is attributable to two essential factors: the genetic
background of the host and the appropriate viral sequences.
FVB/N mice have an H-2
q MHC haplotype and an Hc
0 allele.
Macrophages from the mouse strains carrying the Hc
0 allele do not
secrete complement 5 [32], an important factor in inflammation
and in innate immune responses [33–35], whereas MHC molecules
are involved in antigen presentation. Therefore, we speculate that
the H-2
q allele may represent a special MHC haplotype in mice,
akin to the HLA-DP in humans [17], that induces weaker T-cell
responses against HBV. However, H-2
q per se may not completely
explain the high HBV persistence rates in this mouse strain. We
have other experimental results showing that DBA/1 mice, a strain
that alsocarries the H-2
q allele,wereactuallycapable ofclearing the
HBV DNA with 78% efficiency, albeit over a long period (4–16
weeks, Fig. S6). Therefore, we hypothesize that the additional
defects in the secretion of C5 complement by the macrophages of
FVB/N mice, which leads to lower levels of inflammatory
responses, may constitute another factor contributing to the high
HBV persistence rates. As such, even if some HBV clones could be
cleared in FVB/N mice (e.g., B21, B29, and B6.2S), the lower
inflammatory response still resulted in the delayed clearance of the
HBV DNA in FVB/N mice compared to that in the BALB/c and
C57BL/6 mice (Fig. 5A vs. Fig. 1D).
Recently, many different mouse models have been established
to investigate the pathogenesis and persistence of HBV infection.
The HBV transgenic mice, though invaluable in understanding
the pathogenesis induced by the adoptively transferred CTLs [15],
are inherently tolerant to the transgene products and thus are
unsuitable to address the question of HBV persistence. Many
researchers have established HBV replication models in immuno-
competent nontransgenic mice by employing hydrodynamic
injection [36] or adenoviral vector delivery [37,38], but in most
cases only acute hepatitis can be demonstrated, and the HBV
infection is eventually cleared. Persistent HBV replication in a
mouse model has been demonstrated only under special conditions
in which the HBV DNA was cloned in an adeno-associated viral
(AAV) vector and then delivered to mouse livers either via
hydrodynamic injection [39] or via AAV infection [40]. The
mechanism for this persistence is partly dependent on the AAV
vector, which has been shown to be poorly detected by host innate
immunity and favors long-term persistence in the cells [41,42]. On
the other hand, the HBV persistence in our FVB/N model is most
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36984Figure 7. The levels of ALT, activated CTLs, and the liver expression of cytokines and chemokines in FVB/N mice following injection
with pHBV1.3-B6.2 or -B6.2S DNA. Mice were injected with pHBV1.3-B6.2 or -B6.2S DNA (10 mg/mouse). Three animals were sacrificed at the time
points indicated. (A) Serum ALT levels of the mice were measured. The gray dashed lines represent the normal serum ALT levels, 40 U/L. (B) Flow
cytometric analysis of activated CTLs in the livers. Staining of activated CTLs was performed as described in the legend to Fig. 3B. The liver expression
of (C) IFN-c, (D) TNF-a, (E) CXCL9, and (F) CXCL10 was analyzed by qRT-PCR. Values are shown as the mean 6 SD of three mice. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0036984.g007
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infection in immunocompetent adults usually results in a self-
limited, transient liver disease in more than 95% of patients. FVB/
N mice are akin to the remaining 5% of patients who may have
unique HLAs and induce weaker adaptive and/or innate immune
responses against HBV, thus having a higher tendency of
developing a persistent infection. In concert with this speculation,
genetic variants in MHC genes [11,12], the TNF-a gene [8–10],
and the IFN-c gene [7] have been reported to be associated with
chronic hepatitis B infection in humans.
Our mutagenesis data reveal that FVB/N mice are unable to
clear clone B6.2 but can clear clone B6.2S (Fig. 6). Clone B6.2S
differs from clone B6.2 by just one amino acid. We originally
speculated that the mutation site might have generated a novel
CTL epitope recognizable by FVB/N mice, but our attempts at
demonstrating the presence of such an epitope in this region have
failed. This failure either implies that the mutation does not
generate an epitope or may be due to the low CTL frequency
induced in FVB/N mice. If the former case is true, then we
speculate that the mutation may alternatively induce a conforma-
tional change of the protein and result in a different pattern of
antigen processing, which may create a CTL epitope elsewhere.
However, due to the lack of epitope information for H-2
q and a
suitable cell line carrying this haplotype allowing for a CTL assay,
the speculation that Asn-214 contributes to T-cell tolerance is
unproven and remains to be elucidated.
In summary, the unique H-2
q allele of FVB/N mice may
activate weaker CTL responses after HBV DNA injection, and the
Hc
0 allele concurrently induces lower inflammatory responses;
either or both factors may provide FVB/N mice with the
capability of establishing persistent HBV replication more easily
than would other mouse strains. With the ease of hydrodynamic
injection and the convenience of genetic engineering techniques,
these mouse strains, each with a different susceptibility to
persistent HBV replication, offer a great opportunity to investigate
the host and viral factors associated with HBV persistence in vivo.
Materials and Methods
Ethics statement
Serum samples were collected from the outpatients at National
Taiwan University Hospital with written informed consent. The
study was approved by National Taiwan University Hospital
Research Ethics Committee (Permit Number 200809073R). The
animal study was carried out in strict accordance with the
recommendations in the ‘‘Guide for the Care and Use of
Laboratory Animals’’ of the Council of Agriculture, Taiwan,
and that of the National Institutes of Health, USA. The protocol
has been reviewed and approved by the Institutional Animal Care
and Use Committee of National Yang-Ming University (Approval
No. 971017). All surgery was performed under ketamine and
xylazine anesthesia, and all efforts were made to minimize
suffering.
Construction of HBV replicons
HBV replicons containing a replication-competent 1.3-fold
overlength HBV genome were used for hydrodynamic injection.
To construct the replicons, the full-length HBV genomes were
amplified from clinical isolates of genotype B HBV that were
obtained from serum samples of outpatients at the National
Taiwan University Hospital. HBV DNA was extracted from the
serum using QIAampH DNA Mini Kit (QIAGEN, Hilden,
Germany) following the manufacturer’s instructions and was then
amplified by polymerase chain reaction (PCR) using the primer
pair P1–P2 [43]. The sequences of the primers are shown in Table
S1. The PCR products were cloned in the yT&A vector (Yeastern
Biotech, Taipei, Taiwan). Linear HBV monomers were then
released from the vector by cleavage with 1.5 U of SapI (New
England Biolabs, MA) per mg of DNA for at least 12 h and self-
ligated with T4 DNA ligase. The self-ligated DNAs were used as
the templates for the next PCR. Two sets of primer pairs, Primer-
A1 and -A2 and Primer-B1 and -B2 (Table S1), were used to
amplify fragments A and B, respectively. Fragment A was then
digested with HindIII and XbaI, and fragment B was digested with
XbaI and BglII. The fragments were subsequently cloned into the
HindIII- and BamHI-digested pGEM4Z vector (Promega, Madi-
son, WI) via a tri-molecular ligation. The resulting pGEM4Z/
HBV1.3 replicons contain a 1.3-fold overlength HBV genome
spanning from nucleotide (nt) 971 to nt 3215/1 and nt 1 to nt 1984
(Fig. S1). To represent the quasispecies nature, the pHBV1.3-B6
clone DNA was produced by mixing six sub-clone DNAs (B6.1,
B6.2, B6.3, B6.7, B6.8, and B6.9) at equal ratios, which were
derived from six isolates from the same patient.
Site-directed mutagenesis was performed to generate the
pHBV1.3-B6.2 mutant clones using the previously described
method [44]. The primers used to generate clone B6.2S and clone
B6.2P are Primer-N214S and Primer-H337Y, respectively (Table
S1). For pHBV1.3-B6SP, the site-directed mutagenesis was
performed twice serially to obtain the double mutant clone.
Animal experiments
BALB/c, C57BL/6, and FVB mice (male, 6–8 weeks of age)
obtained from the National Laboratory Animal Center, Taiwan
were housed in a specific pathogen-free room. Ten micrograms of
the HBV plasmid DNA in a volume of PBS equivalent to 8% of
the mouse body weight was introduced by tail vein injection in 6–
8 s. Serum samples were collected at the time points indicated
after DNA injection and assayed for HBeAg and ALT.
Detection of HBeAg and ALT in the serum
Serum levels of HBeAg in the injected mice were determined
using the AXSYM system kit (Abbott GmbH Diagnostica,
Wiesbaden, Germany). Serum ALT activity was measured by an
automated clinical chemistry analyzer TBA-200FR (Toshiba,
Tokyo, Japan) using the ALT/GPT reagent (Denka Seiken,
Tokyo, Japan).
Figure 8. Histological analysis of the livers of FVB/N mice
injected with pHBV1.3-B6.2 or -B6.2S replicon DNA. FVB/N mice
were injected with pHBV1.3-B6.2 or -B6.2S replicon DNA. The mice were
sacrificed at the indicated time points, and their livers were fixed with
formalin, embedded in paraffin, and stained with hematoxylin and
eosin. The arrows indicate the infiltrating inflammatory cells. The scale
bar represents 50 mm. The images are displayed at 4006magnification.
doi:10.1371/journal.pone.0036984.g008
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Twenty micrograms of liver genomic DNA were digested with
HindIII and separated on a 1% agarose gel. The gel was blotted
onto a positively charged nylon membrane (Roche Diagnostics
GmbH, Mannheim, Germany), which was then hybridized with a
digoxigenin-labeled probe encompassing the HBx coding region
(nt 1372–1833), and the signals were detected by exposure to X-
ray films.
Immunohistochemistry
Liver tissues were collected from the mice at the indicated time
points, snap-frozen, and sectioned into 5-mm cryosections. Liver
sections were stained with rabbit anti-HBcAg (1:700 dilution,
DAKO, Carpinteria, CA) or rabbit anti-HBsAg (ad+ay) (1:500
dilution, Biodesign, Saco, ME) antibody and then developed using
the Envision System-HRP, DAB (DAKO) following the manu-
facturer’s instructions. The liver sections were counterstained with
hematoxylin.
Isolation of intrahepatic lymphocytes
IHLs were isolated following the method described previously
[45], with some modifications. Briefly, the livers were perfused with
5 ml of liver digestion medium containing 100 mg/ml collagenase
IV (Sigma-Aldrich, St. Louis, MO) and 10 mg/ml DNase I (Roche
Diagnostics GmbH, Mannheim, Germany) in HBSS. The livers
were then cut into small pieces in 5 ml of the digestion medium and
then incubated for 40 min at 37uC. The small liver pieces were
further homogenized and forced through a metal mesh. The liver
slurry was washed and centrifuged at 506g for 5 min at 4uC. The
supernatant was collected and centrifuged at 3006g for 10 min at
4uC. The cell pellet was resuspended with ice-cold serum-free
RPMI-1640toafinalvolume of4 ml,and4 mlof80%(v/v)Percoll
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden) in RPMI-1640
was added and mixed well. The mixture was layered on the top of
2 ml of 60% (v/v) Percoll in HBSS and centrifuged at 1,2006g for
20 min at room temperature (RT). The IHLs were harvested from
the interface, washed, and used for flow cytometric analysis.
Flow cytometric analysis
IHLs were stained with the following monoclonal antibodies:
peridinin chlorophyll protein (PerCP)-conjugated anti-mouse
CD3e, fluorescein isothiocyanate (FITC)-conjugated anti-mouse
CD8a, and R-Phycoerythrin (R-PE)-conjugated anti-mouse CD69
(all from BD Biosciences, Mountain View, CA). Flow cytometry
data were acquired using a FACSCanto apparatus with FACS-
Diva software (BD Biosciences) and were analyzed using FlowJo
software (Treestar, Inc., San Carlos, CA).
qRT-PCR analysis of cytokine and chemokine gene
expression
Liver RNA was extracted using TRIzolH reagent (Invitrogen,
Carlsbad, CA), and 1 mg of RNA was subjected to reverse
transcription. One twentieth of the cDNA product was then
incubated with specific primers (Table S1) using Fast SYBR Green
Master Mix (Applied Biosystems, Carlsbad, CA). The reaction
mixture was first denatured at 95uC for 20 sec, and 40 cycles of
PCR were performed using the following settings: 95uC for 3 sec
and 60uC for 30 sec. Each reaction was performed in triplicate.
The expression level of each gene was normalized to beta-actin.
Statistical analysis
The HBeAg clearance rates in different groups were compared
using the logrank test. For statistical analysis of two variables, two-
tailed Student’s t-test was used (GraphPad Prism 4 software, San
Diego, CA). A P-value,0.05 was considered statistically signifi-
cant.
Supporting Information
Figure S1 The pGEM4Z/HBV1.3 replicon plasmid. The
pGEM4Z/HBV1.3 vector contains the HBV fragment spanning
from nt 971 to nt 3,215 and from nt 1 to nt 1,984, which contains
a 1.3-fold overlength HBV genome. The restriction enzyme sites
used for construction of pGEM4Z/HBV1.3 are shown.
(TIF)
Figure S2 Flow cytometric analysis of the levels of
activated CTLs in the livers of different mouse strains
after DNA injection. Mice were injected with pHBV1.3-B6
DNA (10 mg/mouse), and three animals were sacrificed at the
indicated time points after DNA injection. Intrahepatic lympho-
cytes were isolated and stained for CD3 (PerCP), CD8 (FITC), and
CD69 (PE). Representative histograms show the CD69 expression
by CD3
+CD8
+ cells within a forward and side scatter gate
appropriate for lymphocytes (solid lines). Lymphocytes were
stained for CD3 (PerCP) and CD8 (FITC) as fluorescence-
minus-one controls (shaded plots).
(TIF)
Figure S3 HBV specific CTL responses detected by IFN-
c ELISPOT assay. The results of IFN-c ELISPOT assays for
BALB/c (A) or C57BL/6 (B) mice are shown. Mice were injected
with pGEM4Z vector or pHBV1.3-B6 DNA (10 mg/mouse), and
three animals were sacrificed at 2 wpi (BALB/c mice) or 3 wpi
(C57BL/6 mice), respectively. The isolated IHLs and splenocytes
of BALB/c mice were stimulated with a peptide pool containing
5 mg/ml of each of the following: P140 (Pol140–148), C131
(HBcAg131–139), and S28 (HBsAg28–39), whereas those of
C57BL/6 mice were stimulated with 5 mg/ml of S190
(HBsAg190–197, H-2K
b-restricted). After 18–20 h of peptide
stimulation, the frequencies of IFN-c-secreting cells were deter-
mined and measured as the number of spot-forming cells (SFC)
per 5610
5 cells. Asterisks mean significant difference between the
HBV DNA- and the vector-injected animals. Results are shown as
the mean 6 SD. **P,0.01; *** P,0.001.
(TIF)
Figure S4 The replication and gene expression efficien-
cies of different HBV isolates. One microgram of pHBV1.3
DNA was transfected into 7610
5 HuH-7 cells. Sixteen hours later,
the transfected cells were subcultured for RNA, DNA, protein,
and luciferase activity analyses. (A) Northern blot analysis shows
HBV gene expression efficiency. Two days after HBV DNA
transfection, total RNA was extracted and analyzed by Northern
blot with an HBV-specific probe and a GAPDH probe. The sizes
corresponding to the HBV transcripts are indicated to the right.
(B) Southern blot analysis shows viral DNA replication efficiency.
Total genomic DNA was harvested three days after HBV DNA
transfection, digested with HindIII, and then analyzed by Southern
blot with an HBV-specific probe. The HBV replicative interme-
diates are indicated to the right. (C) Western blot analysis shows
viral antigens expression. Total proteins were extracted four days
after HBV DNA transfecton and subjected to western blot
analysis. The HBV core protein, S proteins, and a-tubulin are
indicated to the right. (D, E) ELISA determines the HBsAg and
HBeAg levels, respectively. The supernatants were collected on the
3
rd day after HBV DNA transfection, and subjected to ELISA
analysis. (F) Renilla luciferase activity assay shows the transfection
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th day after HBV
DNA transfection and Renilla luciferase activities were analyzed.
(TIF)
Figure S5 No peptide-specific T cell response in FVB
mice. (A) The sequences of the synthetic 15-mer peptides. The
sequences covering the Asn-214 region are shown at the top of the
figure. The four peptides covering the mutated site are depicted by
the lines, namely, LS205-N (L-HBsAg205–219-N), LS210-N (L-
HBsAg210–224-N), LS205-S (L-HBsAg205–219-S), and LS210-S (L-
HBsAg210–224-N), where N and S represent Asn or Ser at the 214
th
residue, respectively. (B) No T cell response specific to the mutated
region was observed in the FVB mice injected with HBV DNA.
FVB mice were hydrodynamically injected with pGEM4Z vector
or pHBV1.3-B6 DNA (10 mg/mouse), and three animals were
sacrificed at 4 wpi. The IHLs were isolated and stimulated with
10 mg/ml of LS205-N, LS210-N, LS205-S, or LS210-S. After 18–
20 h of peptide stimulation, the frequencies of IFN-c-secreting
cells were determined and measured as the number of spot-
forming cells (SFC) per 5610
5 cells. (C) No T cell response specific
to the mutated region was observed in the FVB mice
intramuscularly immunized with HBsAg-expressing DNA. FVB
mice were immunized with control vector or the plasmid DNA
encoding HBsAg-B6.2 or HBsAg-B6.2S (100 mg/mouse). The
animals were boosted with the same dose of DNA every two weeks
for three times. One week after the final boost, HBsAg-specific T-
cell response was examined by IFN-c ELISPOT assays using the
aforementioned peptides. The splenocytes isolated from the
immunized mice (n=3) were stimulated with 10 mg/ml of the
15-mer synthetic peptides as described above. After 18–20 h of
incubation, the frequencies of IFN-c-secreting cells were counted.
(D) A significant HBsAg-specific T cell response was observed in
the C57BL/6 mice. The C57BL/6 mice immunized with a
plasmid DNA encoding the HBsAg-B6.2S served as the positive
control for DNA immunization. One week after the second
immunization, an HBsAg-specific IFN-c ELISPOT assay was
performed on the splenocytes isolated from the immunized mice
(n=3), which were stimulated with 10 mg/ml of HBsAg190–197.
After 18–20 h of peptide stimulation, the spots of IFN-c-secreting
cells were counted. The results are shown as the mean 6 SD.
Asterisks mean significant difference between the peptide stimu-
lated- and medium control- groups. *** P,0.001.
(TIF)
Figure S6 Long-term follow up of serum HBeAg in
DBA/1 mice injected with pHBV1.3-B6 DNA. Ten
micrograms of pHBV1.3-B6 DNA were injected into DBA/1
mice. (A) Serum HBeAg was monitored regularly for up to 16
weeks. Each line represents one animal. (B) The HBeAg clearance
curves in FVB mice and DBA/1 mice are shown. DBA/1 vs. FVB,
*** P,0.001, logrank test.
(TIF)
Table S1 The sequences of primers used for construc-
tion of HBV replicons, site-directed mutagenesis, and
real-time PCR analysis.
(DOC)
Methods S1 IFN-c ELISPOT assay. DNA immunization.
(DOC)
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